Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant

Barchart · 01/07 12:00
Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.